Physical Activity Intervention for Older Patients During Chemotherapy for Colorectal Cancer

N/ACompletedNCT02191969

UNC Lineberger Comprehensive Cancer Center36 enrolled

Overview

This study will see if patient who undergo a physical activity intervention called Walk With Ease report experiencing less fatigue and a higher quality of life during chemotherapy for colorectal cancer than those who do not participate in this intervention.

The primary purpose of this multicenter, randomized controlled study is to evaluate the impact of a physical activity program on fatigue in older patients (≥60 years) undergoing adjuvant chemotherapy for colorectal cancer. The investigators also plan to evaluate physical function and quality of life as secondary objectives. The investigators' hypotheses are that people who undergo the physical activity intervention compared to those who do not, will: 1) report less fatigue, 2) report higher health related quality of life, and 3) have less decline in physical function. Additionally, The investigators will characterize ≥grade 3 adjuvant chemotherapy associated toxicities in this older population, and describe the changes reported in fatigue, physical function, and HRQOL over the course of chemotherapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

Conditions

Colorectal Cancer Fatigue

Interventions

Walk With EaseBEHAVIORAL

A self-directed walking intervention developed by the Arthritis Foundation. The intervention is a workbook that coaches participants through walking regularly at a safe, comfortable pace with the ultimate goal of walking at least 30 minutes a day five days a week.

Eligibility

Sex: ALLMin age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥ Age 60 years (no upper age limit) * Diagnosis of stage II-III colon or rectal cancer planned for treatment with adjuvant chemotherapy scheduled as part of standard treatment * Able to read English (required for CGA and other surveys administered) * Approval from their treating physician to engage in moderate-intensity physical activity * Patient-assessed ability to walk and engage in moderate physical activity * Signed, IRB-approved written informed consent Exclusion Criteria: * Other active, invasive malignancy requiring ongoing therapy or expected to require systemic therapy * Already walking or engaging in other physical activity \>120 minutes per week as documented via subject self-report * Unable to walk or engage in moderate-intensity physical activity * One or more significant medical conditions that in the physician's judgment preclude participation in the walking intervention

Locations (1)

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Outcomes

Primary Outcomes

To measure the change in fatigue after three months between the intervention and control arm

The investigators will compare the change in fatigue from baseline to 3 months between Intervention and Control arms as measured via PROMIS®-Fatigue.

Time frame: Three Months

Secondary Outcomes

To measure changes in physical function at baseline between the intervention and control groups.

To evaluate the following measures at baseline, 3 months, and after completion of chemotherapy and compare changes in these measures over time between Intervention and Control arms. • Physical function as measured by PROMIS-PF and SPPB

Time frame: 4 to 24 weeks

To measure adherence to the physical activity intervention

To report on the adherence of the physical activity intervention as measured through self-reported minutes of walking per days and walking minutes per week in the group randomized to the Intervention arm

Time frame: One Year

To measure the difference in p16INK4a levels before and after chemotherapy in the control and intervention groups

The investigators will comparee the change in p16INK4a and muscle mass measurements pre/post adjuvant chemotherapy between Intervention and Control groups

Time frame: One Year

To measure the change in muscle mass measurements before and after chemotherapy between the intervention and control arms

The investigators will compare the change in p16INK4a and muscle mass measurements pre/post adjuvant chemotherapy between Intervention and Control groups

Time frame: One Year

To measure the association of p16INK4a and muscle mass with any differences in fatigue o physical function or QOL during chemotherapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.